Skip to main content
Frances Collichio, MD, Oncology, Chapel Hill, NC, University of North Carolina Hospitals

FrancesACollichioMD

Oncology Chapel Hill, NC

Clinical Professor of Hematology & Oncology, University of North Carolina School of Medicine

Dr. Collichio is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Collichio's full profile

Already have an account?

Education & Training

  • University of Rochester
    University of RochesterFellowship, Hematology and Medical Oncology, 1992
  • University of Rochester
    University of RochesterResidency, Internal Medicine, 1987 - 1990
  • University of Rochester School of Medicine and Dentistry
    University of Rochester School of Medicine and DentistryClass of 1987

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 1998 - 2025
  • NY State Medical License
    NY State Medical License 1988 - 1999
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • ASCO Education Council 2017-2018
  • Regional Top Doctor Castle Connolly, 2014
  • Co-Chair ASH/ASCO Curricular Milestones Commitee ASH and ASCO
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Milestones 2.0 and Harmonized Milestones 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

  • Parental Leave in Graduate Medical Education: Recommendations for Reform
    Parental Leave in Graduate Medical Education: Recommendations for ReformNovember 29th, 2018
  • Revolutionizing Immune and Target Therapies
    Revolutionizing Immune and Target TherapiesSeptember 17th, 2015
  • Injecting Genetically Modified Virus into Tumor May Treat Metastatic Melanoma
    Injecting Genetically Modified Virus into Tumor May Treat Metastatic MelanomaJanuary 31st, 2019

Grant Support

  • Clinical Trial: Lccc 0424: Phase I Erlotinib Given Every 72 Hours To Patients WNational Center For Research Resources2008

Committees

  • Member, ACGME Hematology Oncology Milestones 2018 - 2018

Professional Memberships

Hospital Affiliations